|
1.Ma Z, Li H, Zhang Y, Zhang L, Huang G, Zhang Y, Shi L, Liu W, An Z, Guan X*. Prevalence of aggressive care
among patients with cancer near the end of life: a systematic review and meta-analysis.
EClinicalMedicine. 2024 Mar 21;71:102561. (SCIE, Q1, IF-2022=15.1)
2.Du K, Wushouer H, Huang T, Zhou Y, Hu L, Yang Y, Deng Y, Zheng B, Guan X*, Shi L*. The changes of different
restriction level adjustments on antibiotic use in China.
Int J Antimicrob Agents. 2023 Dec 21:107073. (SCIE, Q1, IF-2022=10.8)
3.Zhang Y, Chen D, Cheng S, Liang Z, Yang L, Li Q, Bai L, Li H, Liu W, Shi L, Guan X*. Use of suboptimal control
arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study.
PLoS Med. 2023 Dec 12;20(12):e1004319.8.(SCIE, Q1, IF-2022=15.8)
4.Hu L, Fu M, Wushouer H, Ling K, Shi L, Guan X*. Association Between β-lactam Allergy Documentation and
Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China.
J Hosp Infect. 2023 Sep 1:S0195-6701(23)00282-7.(SCIE, Q1, IF-2022=6.9)
5.Fu M, Gong Z, Li C, Ling K, Zhu Y, Li H, Shi L, Guan X*. Appropriate use of antibiotics for acute respiratory
infections at primary healthcare facilities in China: a nationwide cross-sectional study from 2017 to 2019.
Lancet Reg Health West Pac. 2023 Aug 18;40:100880.(SCIE, SSCI, Q1, IF-2022=7.1)
6.Yang Y, Zhang Y, Wagner AK, Li H, Shi L, Guan X*. The impact of government reimbursement negotiation on
targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
J Glob Health. 2023 Aug 11;13:04083.(SCIE, SSCI, Q1, IF-2022=7.2)
7.Bai L, Zhan Y, Zhou Y, Zhang Y, Shi L, Gupta S, Denburg A, Guan X*. Evidence of clinical benefit of WHO
essential anticancer medicines for children, 2011-2021. EClinicalMedicine.
2023 Apr 12;59:101966. (SCIE, Q1, IF-2022=15.1)
8.Wushouer H, Zhou Y, Zhang W, Hu L, Du K, Yang Y, Yao G, Little P, Zheng B, Guan X*, Shi L. Inpatient
antibacterial use trends and patterns, China, 2013-2021.
Bull World Health Organ. 2023 Apr 1;101(4):248-261B. (SCIE, Q1, IF-2022=11.1)
9.Zhang Y, Wagner AK, Guan X*. Newly approved cancer drugs in China - innovation and clinical benefit.
Nat Rev Clin Oncol. 2023 Mar;20(3):135-136. (SCIE, Q1, IF-2022=78.8)
10.Fu M, Zhu Y, Gong Z, Li C, Li H, Shi L*, Guan X*. Benzodiazepine Receptor Agonists Prescribing for
Insomnia Among Adults in Primary Health Care Facilities in Beijing, China. JAMA Netw Open.
2023 Feb 1;6(2):e230044. (SCIE, Q1, IF-2022=13.8)
11.Wushouer H, Yang Y, Deng Y, Zheng B, Shi L, Guan X*. A comparative study of antibiotic use in
China under Chinese restriction list and world health Organization AWaRe classification.
Clin Microbiol Infect. 2022 Dec 13:S1198-743X(22)00631-0. (SCIE, Q1, IF-2022=14.2)
12.Fu M, Gong Z, Zhu Y, Li C, Zhou Y, Hu L, Li H, Wushouer H, Guan X*, Shi L. Inappropriate
antibiotic prescribing in primary healthcare facilities in China: a nationwide survey, 2017-2019.
Clin Microbiol Infect. 2022 Nov 25:S1198-743X(22)00587-0. (SCIE, Q1, IF-2022=14.2)
13.Zhang Y, Naci H, Wagner AK, Xu Z, Yang Y, Zhu J, Ji J, Shi L, Guan X*. Overall Survival Benefits
of Cancer Drugs Approved in China From 2005 to 2020. JAMA Netw Open.
2022;5(8):e2225973. (SCIE, Q1, IF-2022=13.8)
14.Zhang Y, Guan X. Misleading Reporting in Statistically Not Significant Oncology Trials-Joining
Efforts Toward Unbiased Results Interpretation. JAMA Netw Open.
2021 Dec 1;4(12):e2138695. (SCIE, Q1, IF-2021=13.36)
15.Naci H, Guan X, Woloshin S, Xu Z, Wagner AK. Communication of Survival Data in US Food and Drug
Administration-Approved Labeling of Cancer Drugs. JAMA Intern Med.
2021 Nov 1;181(11):1521-1522. (SCIE, Q1, IF-2021=44.424)
16.Fu M, Naci H, Booth C, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner A.
Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.
JAMA Intern Med. 2021 Oct 18;e215983. (SCIE, Q1, IF-2021=44.424)
17.Huang T, Wagner A, Bai L, Huang C, Guan X*, Shi L. Anticancer medicines in China: Trends in
daily therapy cost and relative procurement volume and spending. Cancer Commun (Lond).
2021 Apr;41(4):345-348.(SCIE, Q1, IF-2021=15.283)
18.贺子璇,黄先琴,陈定一,王国安,朱玥桢,韩晟,管晓东*,史录文.中国国家医保谈判药品药物经济学评价研究的系统评价
[J].中国循证医学杂志,2023,23(02):159-169.
19.杨雨,胡华杰,黄涛,巩志文,管晓东*,史录文.医务人员“共诊患者”网络研究的范围综述[J].
中国循证医学杂志,2023,23(02):197-202.
20.保琦,胡琳,胡华杰,黄涛,傅孟元,海沙尔江·吾守尔,管晓东*,史录文.超说明书用药医疗损害责任纠纷判决与循证证据
的相关性分析[J].中国药房,2022,33(15):1810-1813+1819.
|
